Do analysts prefer XTLB or AIMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer TPST or XTLB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TPST or XTLB more profitable?

XTL Biopharmaceuticals' return on equity of 0.00% beat Tempest Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tempest Therapeutics N/A -355.61% -121.21% XTL Biopharmaceuticals N/A N/A N/A

Do analysts recommend LPCN or XTLB?

Lipocine currently has a consensus price target of $15.00, suggesting a potential upside of 563.72%. Given Lipocine's stronger consensus rating and higher possible upside, analysts plainly believe Lipocine is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate NCEL or XTLB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, NCEL or XTLB?

XTL Biopharmaceuticals has higher revenue and earnings than NLS Pharmaceutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A XTL Biopharmaceuticals $450K 10.41 -$1.03M -$0.64 N/A

Is NCEL or XTLB more profitable?

Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A XTL Biopharmaceuticals N/A N/A N/A

Do analysts rate CTXR or XTLB?

Citius Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 825.93%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than XTL Biopharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 XTL Biopharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CTXR or XTLB more profitable?

XTL Biopharmaceuticals' return on equity of 0.00% beat Citius Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Citius Pharmaceuticals N/A -61.09% -35.36% XTL Biopharmaceuticals N/A N/A N/A

XTL Biopharmaceuticals (XTLB) Competitors

$2.13 -0.21 (-8.97%)

Closing price 04:00 PM Eastern

Extended Trading

$2.04 -0.09 (-4.18%)

As of 07:50 PM Eastern

Compare

XTLB vs. AIMD, TPST, LPCN, NCEL, and CTXR

Should you buy XTL Biopharmaceuticals stock or one of its competitors? MarketBeat compares XTL Biopharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with XTL Biopharmaceuticals include Ainos (AIMD), Tempest Therapeutics (TPST), Lipocine (LPCN), NLS Pharmaceutics (NCEL), and Citius Pharmaceuticals (CTXR). These companies are all part of the "med - drugs" industry.

How does XTL Biopharmaceuticals compare to Ainos?

XTL Biopharmaceuticals (NASDAQ:XTLB) and Ainos (NASDAQ:AIMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

XTL Biopharmaceuticals has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. XTL Biopharmaceuticals' return on equity of 0.00% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTL Biopharmaceuticals	N/A	N/A	N/A
Ainos	-11,912.10%	-160.55%	-62.29%

4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by company insiders. Comparatively, 9.8% of Ainos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Ainos had 1 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 3 mentions for Ainos and 2 mentions for XTL Biopharmaceuticals. XTL Biopharmaceuticals' average media sentiment score of 1.44 beat Ainos' score of 0.48 indicating that XTL Biopharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
XTL Biopharmaceuticals	Positive
Ainos	Neutral

XTL Biopharmaceuticals has higher revenue and earnings than Ainos. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTL Biopharmaceuticals	$450K	10.41	-$1.03M	-$0.64	N/A
Ainos	$120K	135.61	-$14.77M	-$2.89	N/A

XTL Biopharmaceuticals has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, Ainos has a beta of 2.41, indicating that its stock price is 141% more volatile than the broader market.

Summary

XTL Biopharmaceuticals beats Ainos on 9 of the 12 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Tempest Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, XTL Biopharmaceuticals had 1 more articles in the media than Tempest Therapeutics. MarketBeat recorded 2 mentions for XTL Biopharmaceuticals and 1 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 1.87 beat XTL Biopharmaceuticals' score of 1.44 indicating that Tempest Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tempest Therapeutics	Very Positive
XTL Biopharmaceuticals	Positive

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 6.3% of Tempest Therapeutics shares are owned by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Tempest Therapeutics has a beta of -1.85, meaning that its stock price is 285% less volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

XTL Biopharmaceuticals has higher revenue and earnings than Tempest Therapeutics. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$6.01	N/A
XTL Biopharmaceuticals	$450K	10.41	-$1.03M	-$0.64	N/A

XTL Biopharmaceuticals' return on equity of 0.00% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-355.61%	-121.21%
XTL Biopharmaceuticals	N/A	N/A	N/A

Summary

XTL Biopharmaceuticals beats Tempest Therapeutics on 8 of the 11 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Lipocine?

Lipocine (NASDAQ:LPCN) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

XTL Biopharmaceuticals has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. XTL Biopharmaceuticals' return on equity of 0.00% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-571.18%	-66.70%	-59.39%
XTL Biopharmaceuticals	N/A	N/A	N/A

In the previous week, Lipocine and Lipocine both had 2 articles in the media. XTL Biopharmaceuticals' average media sentiment score of 1.44 beat Lipocine's score of 0.94 indicating that XTL Biopharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Lipocine	Positive
XTL Biopharmaceuticals	Positive

9.1% of Lipocine shares are held by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 6.4% of Lipocine shares are held by company insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Lipocine currently has a consensus price target of $15.00, suggesting a potential upside of 563.72%. Given Lipocine's stronger consensus rating and higher possible upside, analysts plainly believe Lipocine is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lipocine has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

XTL Biopharmaceuticals has lower revenue, but higher earnings than Lipocine. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	9.41	-$9.63M	-$1.88	N/A
XTL Biopharmaceuticals	$450K	10.41	-$1.03M	-$0.64	N/A

Summary

XTL Biopharmaceuticals beats Lipocine on 9 of the 14 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

NLS Pharmaceutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market.

XTL Biopharmaceuticals has higher revenue and earnings than NLS Pharmaceutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
XTL Biopharmaceuticals	$450K	10.41	-$1.03M	-$0.64	N/A

In the previous week, NLS Pharmaceutics and NLS Pharmaceutics both had 2 articles in the media. XTL Biopharmaceuticals' average media sentiment score of 1.44 beat NLS Pharmaceutics' score of 0.94 indicating that XTL Biopharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
NLS Pharmaceutics	Positive
XTL Biopharmaceuticals	Positive

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
XTL Biopharmaceuticals	N/A	N/A	N/A

4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 16.4% of NLS Pharmaceutics shares are held by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

XTL Biopharmaceuticals beats NLS Pharmaceutics on 6 of the 6 factors compared between the two stocks.

How does XTL Biopharmaceuticals compare to Citius Pharmaceuticals?

Citius Pharmaceuticals (NASDAQ:CTXR) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

XTL Biopharmaceuticals has higher revenue and earnings than Citius Pharmaceuticals. XTL Biopharmaceuticals is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Pharmaceuticals	N/A	N/A	-$37.43M	-$2.13	N/A
XTL Biopharmaceuticals	$450K	10.41	-$1.03M	-$0.64	N/A

Citius Pharmaceuticals presently has a consensus price target of $5.00, indicating a potential upside of 825.93%. Given Citius Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Citius Pharmaceuticals is more favorable than XTL Biopharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
XTL Biopharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Citius Pharmaceuticals and Citius Pharmaceuticals both had 2 articles in the media. XTL Biopharmaceuticals' average media sentiment score of 1.44 beat Citius Pharmaceuticals' score of 0.76 indicating that XTL Biopharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Citius Pharmaceuticals	Positive
XTL Biopharmaceuticals	Positive

Citius Pharmaceuticals has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market. Comparatively, XTL Biopharmaceuticals has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market.

XTL Biopharmaceuticals' return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Pharmaceuticals	N/A	-61.09%	-35.36%
XTL Biopharmaceuticals	N/A	N/A	N/A

16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 5.0% of Citius Pharmaceuticals shares are held by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

XTL Biopharmaceuticals beats Citius Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

Get XTL Biopharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

XTLB vs. The Competition

Export

Metric	XTL Biopharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.16M	$2.98B	$6.49B	$11.98B
Dividend Yield	N/A	1.78%	2.67%	5.57%
P/E Ratio	N/A	18.07	23.85	24.45
Price / Sales	10.41	757.81	572.24	136.74
Price / Cash	N/A	56.09	43.20	54.62
Price / Book	0.86	4.01	10.66	6.80
Net Income	-$1.03M	$75.85M	$3.56B	$337.76M
7 Day Performance	3.40%	1.07%	0.05%	2.08%
1 Month Performance	-18.39%	-3.27%	0.37%	3.16%
1 Year Performance	N/A	20.00%	22.73%	27.78%

XTL Biopharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
XTLB XTL Biopharmaceuticals	1.2864 of 5 stars	$2.13 -9.0%	N/A	N/A	$5.16M	$450K	N/A	N/A	Positive News Short Interest Decrease Gap Down
AIMD Ainos	0.6355 of 5 stars	$2.20 -6.8%	N/A	-30.9%	$20.12M	$120K	N/A	40	Short Interest Increase
TPST Tempest Therapeutics	2.5202 of 5 stars	$1.27 -3.1%	N/A	-83.3%	$19.40M	N/A	N/A	20	Positive News
LPCN Lipocine	4.4235 of 5 stars	$2.19 -2.7%	$15.00 +584.9%	-33.9%	$18.55M	$1.98M	N/A	10	News Coverage Gap Down
NCEL NLS Pharmaceutics	1.245 of 5 stars	$3.16 -4.8%	N/A	-86.5%	$17.75M	N/A	N/A	6	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:XTLB) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

XTL Biopharmaceuticals (XTLB) Competitors

XTLB vs. AIMD, TPST, LPCN, NCEL, and CTXR

How does XTL Biopharmaceuticals compare to Ainos?

Summary

How does XTL Biopharmaceuticals compare to Tempest Therapeutics?

Summary

How does XTL Biopharmaceuticals compare to Lipocine?

Summary

How does XTL Biopharmaceuticals compare to NLS Pharmaceutics?

Summary

How does XTL Biopharmaceuticals compare to Citius Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB vs. The Competition

XTL Biopharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

XTL Biopharmaceuticals (XTLB) Competitors

XTLB vs. AIMD, TPST, LPCN, NCEL, and CTXR

How does XTL Biopharmaceuticals compare to Ainos?

Is XTLB or AIMD more profitable?

Do insiders and institutionals hold more shares of XTLB or AIMD?

Do analysts prefer XTLB or AIMD?

Does the media prefer XTLB or AIMD?

Which has stronger earnings and valuation, XTLB or AIMD?

Which has more risk and volatility, XTLB or AIMD?

Summary

How does XTL Biopharmaceuticals compare to Tempest Therapeutics?

Do analysts prefer TPST or XTLB?

Does the media refer more to TPST or XTLB?

Do insiders & institutionals believe in TPST or XTLB?

Which has more risk & volatility, TPST or XTLB?

Which has stronger valuation & earnings, TPST or XTLB?

Is TPST or XTLB more profitable?

Summary

How does XTL Biopharmaceuticals compare to Lipocine?

Is LPCN or XTLB more profitable?

Does the media refer more to LPCN or XTLB?

Do institutionals and insiders believe in LPCN or XTLB?

Do analysts recommend LPCN or XTLB?

Which has more risk and volatility, LPCN or XTLB?

Which has preferable earnings and valuation, LPCN or XTLB?

Summary

How does XTL Biopharmaceuticals compare to NLS Pharmaceutics?

Which has more risk and volatility, NCEL or XTLB?

Which has better earnings and valuation, NCEL or XTLB?

Does the media favor NCEL or XTLB?

Is NCEL or XTLB more profitable?

Do institutionals & insiders believe in NCEL or XTLB?

Do analysts rate NCEL or XTLB?

Summary

How does XTL Biopharmaceuticals compare to Citius Pharmaceuticals?

Which has better earnings & valuation, CTXR or XTLB?

Do analysts rate CTXR or XTLB?

Does the media prefer CTXR or XTLB?

Which has more volatility & risk, CTXR or XTLB?

Is CTXR or XTLB more profitable?

Do insiders and institutionals believe in CTXR or XTLB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

XTLB vs. The Competition

XTL Biopharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools